Overview

eIMPACT Trial: Modernized Collaborative Care to Reduce the Excess CVD Risk of Older Depressed Patients

Status:
Completed
Trial end date:
2021-03-01
Target enrollment:
Participant gender:
Summary
The objective of this randomized controlled trial is to evaluate whether the investigators modernized IMPACT intervention for depression (eIMPACT), delivered before the onset of cardiovascular disease (CVD), reduces the risk of future CVD. Participants will be primary care patients who are depressed but do not have a history of CVD. Half of the participants will receive standard depression treatment in primary care (usual care), and the other half will receive one year of eIMPACT, a collaborative stepped care program including antidepressants and computerized and telephonic cognitive-behavioral therapy. To evaluate change in CVD risk, the investigators will measure artery function using ultrasound before and after the 1-year treatment period. It is hypothesized that patients who receive the eIMPACT intervention will have greater improvements in artery function than patients who receive usual care.
Phase:
Phase 2
Details
Lead Sponsor:
Indiana University
Collaborator:
National Heart, Lung, and Blood Institute (NHLBI)
Treatments:
Antidepressive Agents
Dopamine
Dopamine Uptake Inhibitors
Norepinephrine
Serotonin
Serotonin Uptake Inhibitors